Document:

EX-10.7

 EXHIBIT 10.7 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 FIRST AMENDMENT TO LICENSE AGREEMENT 

This first amendment (“First Amendment”) is entered into and effective as of July 1, 2009, by and between PHRI Properties,
Inc., a nonprofit corporation of the State of New Jersey having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI PROPERTIES”) and Oxford Immunotec Limited, an English company having offices at 94C Milton Park,
Abingdon, Oxfordshire OX14 4RY, United Kingdom (“OXFORD IMMUNOTEC”), collectively “the Parties.”. This First Amendment amends the License Agreement (the “Agreement”) having an effective date of June 30, 2006, by
and between The Public Health Research Institute of The City of New York, Inc., a not-for-profit research corporation of the State of New York having offices at 225 Warren Street, Newark, New Jersey 07103, United States (“PHRI”), and
OXFORD IMMUNOTEC. PHRI PROPERTIES is the assignee of PHRI to its rights and obligations under the Agreement. 
  

	 	1.	PHRI PROPERTIES shall be substituted in the Agreement in each instance where PHRI appears. 

  

	 	2.	A new definition is added to the Agreement as Section 1.16, as follows: 

 1.16
“Average Net Sales Price” shall apply to performance of a Licensed Assay utilizing a Licensed Product in a country or region (as specified below) only when Straight Sales of Licensed Products that are distributed to third parties in that
country or region in a reporting period constitute at least [***] percent ([***]%) of the total number of (i) Licensed Products that are distributed to third parties and (ii) Licensed Products that are used in Licensed Assays performed by
OXFORD IMMUNOTEC and its Affiliates in that country or region in the reporting period. “Average Net Sales Price” shall mean the mean Net Sales Price of Straight Sales of the Licensed Products to third parties in the same country or region
during the reporting period, but not less than the minimum amount specified below. Countries and regions, and applicable minimum amounts of Average Net Sales Price for each are: 

United States of America, [***] US dollars 

United Kingdom, [***] British pounds 

Europe outside the United Kingdom, [***] Euros 

Canada, [***] US dollars 
 Mexico,
Central America, South America, and the Caribbean, [***] US dollars 
 Middle East, [***] Euros 

Africa, [***] Euros 
 Australia
and New Zealand, [***] US dollars 
 Asia, [***] Euros 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	3.	Section 4.4 of the Agreement is amended and completely restated to read, as follows: 

 4.4
Earned Royalties. OXFORD IMMUNOTEC shall pay to PHRI PROPERTIES an earned royalty for each distribution of a Licensed Product and for each performance of a Licensed Assay, as follows: 

 

	 	(a)	for each distribution of a Licensed Product by OXFORD IMMUNOTEC or an Affiliate to a third party, [***] percent ([***]%) of the Net Sales Price; 

 

	 	(b)	for each performance of a Licensed Assay by OXFORD IMMUNOTEC or an Affiliate that utilizes a Licensed Product, [***] percent ([***]%) of the Average Net Sales Price, if Average Net Sales Price is applicable under
Section 1.16: or 

  

	 	(c)	for each performance of a Licensed Assay by OXFORD IMMUNOTEC or an Affiliate not falling within subsection (b) above, [***] percent ([***]%) of Net Service Revenues. 

Royalties under this Section 4.4 shall be payable on a Licensed Product-by-Licensed Product basis or Licensed Assay-by-Licensed Assay
basis for so long as there are Valid Claims of PHRI PROPERTIES Patent Rights covering that Licensed Product or that Licensed Assay. Only one royalty shall he due for a Licensed Product or for a Licensed Assay. 

 

	 	4.	Section 5.2 is amended to additionally require that OXFORD IMMUNOTEC shall, with respect to any earned royalty payment paid under Section 4.4(b), report, by country or region, (i) the total number of
Licensed Products distributed to third parties in the reporting period, (ii) the total number of Licensed Products used in Licensed Assays performed by OXFORD IMMUNOTEC or its Affiliates in the reporting period, and (iii) the number of
Licensed Products sold to third parties at each Net Sales Price during the reporting period. 

 IN WITNESS WHEREOF, the
Parties have set their hands and seals and duly executed this Agreement on the date(s) indicated below. 
  

									
	OXFORD IMMUNOTEC LIMITED	 		 	PHRI PROPERTIES, INC.
					
	By:	 	 /s/ Simon Turner
	 		 	By:	 	 /s/ Francis X. Colford

		 	Simon Turner	 		 		 	Francis X. Colford
		 	Vice President, Finance and Administration	 		 		 	Chief Financial Officer
					
	Date:	 	 29 June 2009
	 		 	Date:	 	  

  
 -2-EX-10.8

 EXHIBIT 10.8 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Second Amendment 

This second amendment (“Second Amendment”) is entered into and effective as of January 6th, 2011, by and between the University
of Medicine and Dentistry of New Jersey (“UMDNJ”), a body corporate and politic of the State of New Jersey, having an office at 1 World’s Fair Drive, Somerset, NJ 08873, successor to The Public Health Research Institute of the City of
New York, Inc., a not-for-profit research corporation of the State of New York, Inc., by virtue of an acquisition of assets completed in December 2006, and Oxford Immunotec Limited, an English company having offices at 94C Milton Park, Abingdon,
Oxfordshire OX14 4RY, United Kingdom (“OXFORD IMMUNOTEC”). This Second Amendment amends the License Agreement having an effective date of June 30, 2006 by and between the Public Health Research Institute of The City of New York, Inc.,
a not-for-profit research corporation of the State of New York having offices at 225 Warren Street, Newark, New Jersey 07103, United States and OXFORD IMMUNOTEC (the “License Agreement”), as previously amended by the first amendment to the
License Agreement effective July 1, 2009 (the “First Amendment”). As amended by both this Second Amendment and the First Amendment, the License Agreement is hereby referred to as the “Agreement”. 

1. (a) UMDNJ represents and warrants that it is the successor to The Public Health Research Institute of the City of New York, Inc., a
not-for-profit research corporation of the State of New York, Inc. as a result of the acquisition of assets of The Public Health Research Institute of the City of New York, Inc. by UMDNJ in December 2006, and that it is further the assignee of all
the patent rights licensed by The Public Health Research Institute of the City of New York, Inc. to OXFORD IMMUNOTEC pursuant to the License Agreement. 

(b) The parties acknowledge that the First Amendment improperly substituted PHRI Properties, Inc. as the assignee of The Public Health
Research Institute of the City of New York, Inc., instead of UMDNJ. The parties further acknowledge that OXFORD IMMUNOTEC has been providing reports and payments to either The Public Health Research Institute of the City of New York, Inc., or PHRI
Properties, Inc. since 2006 and not to UMDNJ. UMDNJ waives, on its behalf and on behalf of any predecessor in interest to its rights under this Agreement, any claims against OXFORD IMMUNOTEC for failure to timely and fully comply with the terms of
the Agreement to the extent that OXFORD IMMUNOTEC made reports and payments to The Public Health Research Institute of the City of New York, Inc., or to PHRI Properties, Inc. rather than to UMDNJ. 

(c) All references in the License Agreement or the First Amendment to PHRI or PHRI Properties shall hereafter mean UMDNJ and the term
“UMDNJ Patent Rights” shall hereafter be substituted for “PHRI Patent Rights”. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 2. The first six lines of Section 1.16 of the Agreement are hereby deleted and replaced
with the following language: 
 “Average Net Sales Price” shall apply to performance of a Licensed Assay utilizing a Licensed
Product in a country or region (as specified below) when there are any Straight Sales of Licensed Products that are distributed to third parties in that country or region in a reporting period. 

3. Section 4.4(a) of the Agreement is hereby modified by adding “or” at the end after the semi-colon; Section 4.4(b) of
the Agreement is hereby modified by deleting the semi-colon and the word “or” at the end; Section 4.4(c) of the Agreement is hereby deleted in its entirety. 

4. Section 6.4(c) of the Agreement is amended by adding the following sentence at the end of the Section: 

Notwithstanding the foregoing, the overall liability cap for OXFORD IMMUNOTEC for calendar years 2010, 2011 and 2012 shall be $[***] for each
of those calendar years. 
 5. Section 9 of the Agreement is deleted in its entirety and replaced with the following: 

OXFORD IMMUNOTEC shall serve notice that the Licensed Product is covered by issued patents or patent applications which constitute the UMDNJ
Patent Rights, but the notice shall not include any reference to UMDNJ or the license granted by this Agreement. OXFORD IMMUNOTEC may continue to use advertising and promotional literature for the marketing of Licensed Products which contain a
reference to a license from The Public Health Research Institute until such time as existing supplies of such marketing materials are exhausted; provided, however, that OXFORD IMMUNOTEC must cease use of such material no later than the second
anniversary of the date of this Second Amendment. OXFORD IMMUNOTEC agrees that it shall remove any reference to a license from The Public Health Research Institute from each of its package inserts for the Licensed Product on the next occasion that
such package insert is submitted to regulatory authorities for approval of other changes to the insert. For purposes of this Section of the Agreement, package inserts shall not be considered advertising or promotional literature with a specific
deadline for cessation of use. 
 6. Section 18.2 of the Agreement is amended to delete all text after the colon and replacing it with
the following: 
 For UMDNJ 

For financial matters, including the reporting of royalties: 

Laura M. Schepps 
 Director,
Finance and Administration 
 University of Medicine and Dentistry of New Jersey 

Office of Patents and Licensing 

1 World’s Fair Drive, Suite 2100 

Somerset, NJ 08873 

  
 2 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 For all other matters: 

Vincent A. Smeraglia 
 Director,
Office of Patents and Licensing 
 University of Medicine and Dentistry of New Jersey 

Office of Patents and Licensing 

1 World’s Fair Drive, Suite 2100 

Somerset, NJ 08873 
 For OXFORD
IMMUNOTEC: 
 Oxford Immunotec Ltd. 

94C Milton Park 
 Abingdon,
Oxfordshire OX14 4RY 
 United Kingdom 

Attn.: Vice President, Finance and Administration 

7. All remaining terms of the License Agreement and First Amendment not superseded or replaced in this Second Amendment shall remain in full
force and effect. 
 IN WITNESS WHEREOF, authorized representatives of each party hereto have duly executed this Second Amendment on the date(s) indicated
below. 
  

									
	OXFORD IMMUNOTEC	 		 	UMDNJ
					
	By	 	 /s/ Peter Wrighton-Smith
	 		 	By	 	 /s/ Denise Mulkern

					
	By	 	 Dr. Peter Wrighton-Smith
	 		 	By	 	 Denise Mulkern

					
	Title	 	 CEO
	 		 	Title	 	 Sr. VP of Finance

					
	Date	 	 6th Jan 2011
	 		 	Date	 	 1/24/11

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]